Media stories about Spectranetics Corp (NASDAQ:SPNC) have been trending somewhat positive recently, Accern Sentiment reports. The research group identifies positive and negative media coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Spectranetics Corp earned a media sentiment score of 0.12 on Accern’s scale. Accern also assigned news headlines about the medical equipment provider an impact score of 46.4007770964473 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Spectranetics Corp (NASDAQ:SPNC) remained flat at $$38.45 during midday trading on Friday. 1,728,900 shares of the company traded hands, compared to its average volume of 788,356. The company has a current ratio of 1.92, a quick ratio of 1.43 and a debt-to-equity ratio of 7.61. Spectranetics Corp has a 12-month low of $19.80 and a 12-month high of $38.55.
Several equities research analysts have recently commented on the stock. Royal Bank Of Canada reaffirmed a “hold” rating and set a $27.00 price target on shares of Spectranetics Corp in a research report on Monday, July 24th. Raymond James Financial, Inc. reissued a “market perform” rating and issued a $28.00 target price on shares of Spectranetics Corp in a report on Tuesday, July 25th. Stifel Nicolaus lowered shares of Spectranetics Corp from a “buy” rating to a “hold” rating in a report on Thursday, August 3rd. Needham & Company LLC lowered shares of Spectranetics Corp from a “buy” rating to a “hold” rating in a report on Friday, August 4th. Finally, Guggenheim lowered shares of Spectranetics Corp from a “buy” rating to a “neutral” rating in a report on Friday, August 4th. Ten research analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $35.36.
The Spectranetics Corporation develops, manufactures, markets and distributes single-use medical devices used in minimally invasive procedures within the cardiovascular system. The Company’s products are used to cross, prepare and treat arterial blockages in the heart and legs and to manage pacemaker and defibrillator cardiac leads.
What are top analysts saying about Spectranetics Corp? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Spectranetics Corp and related companies.